ArticleACS omega2025
Discovery of Sphingosine-1-Phosphate Receptor Modulators as Potential CHI3L1 Inhibitors by Ligand-Based Virtual Screening and Molecular Dynamics Simulations.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Selective Brain-Penetrant TTBK1 Inhibitors Modulate TDP-43 Pathology and Rescue Cognitive Deficits in a Mouse Model of TDP-43 Proteinopathy.Journal of medicinal chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis is characterized by central nervous system inflammation, demyelination, and neuronal degeneration. Current diagnostic and prognostic methods lack precision, necessitating biomarkers for personalized treatment strategies. Chitinase 3-like 1 (CHI3L1) has emerged as a potential prognostic marker, with elevated levels correlating with disease severity and relapse risk. Despite its therapeutic potential, few CHI3L1 inhibitors have been identified. Using ligand-based virtual screening and molecular dynamics simulations, Food and Drug Administration-approved drugs have been screened as CHI3L1 inhibitors with the final goals of being repurposed in MS and other inflammatory diseases, offering promising therapeutic approaches. This investigation suggests that sphingosine-1-phosphate receptor modulators such as fingolimod could be potential inhibitors for CHI3L1.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.